Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study Post published:October 13, 2021 Post category:Press Release
MindMed Joins Clinical Trials Transformation Initiative Post published:October 13, 2021 Post category:Press Release
PharmaTher Granted FDA Orphan Drug Designation For Ketamine To Treat Complex Regional Pain Syndrome Post published:October 13, 2021 Post category:Press Release
MYND Diagnostics Inc. Announces Participation in a Monash University (Australia) Proposal for $3 Million Clinical Trial Post published:October 13, 2021 Post category:Press Release
atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD) Post published:October 11, 2021 Post category:Press Release
Numinus Upgrades Psychedelics Lab to Increase Research Service Capabilities Post published:October 8, 2021 Post category:Press Release
Psyched Wellness Announces Commencement of Next Pre-Clinical Study on AME-1 Post published:October 7, 2021 Post category:Press Release
Tryp Therapeutics Announces Collaboration with Researchers at the University of Wisconsin-Madison Post published:October 7, 2021 Post category:Press Release
MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidiary – MYND Diagnostics Ltd. Post published:October 7, 2021 Post category:Press Release
PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinsonās Disease Post published:October 6, 2021 Post category:Press Release